HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

OVA 323-339

peptide from ovalbumin (323-339)

Also Known As:

OVA (323-339); ovalbumin peptide (323-339); ovalbumin peptide 323-339

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dériaud, Edith: 1 article (11/2018)
2.	Job, Aurélie: 1 article (11/2018)
3.	Leclerc, Claude: 1 article (11/2018)
4.	Lo-Man, Richard: 1 article (11/2018)
5.	Roy, Olivier: 1 article (11/2018)
6.	Szekely, Thomas: 1 article (11/2018)
7.	Taillefumier, Claude: 1 article (11/2018)
8.	Aardal, N P: 1 article (05/2010)
9.	Aasen, T B: 1 article (05/2010)
10.	Elsayed, S: 1 article (05/2010)

Related Diseases

1.	Neoplasms (Cancer) 11/21/2003 - "However, only mice immunized with HER2 (16-30) and HER2 (63-71), but not with a tumor-unrelated OVA (323-339) and HER2 (63-71), showed in vivo eradication of CMS5mHE tumor cells expressing HER2 but not OVA. " 11/21/2003 - "Conversely, both HER2 (16-30) and OVA (323-339) Th epitopes were equally effective in inducing the eradication of CMS5mHEOVA tumor cells which express HER2 as well as OVA. " 11/08/2018 - "We present here for the first time the synthesis and immunological evaluation of a fully synthetic three-component anticancer vaccine candidate that consists of a β-glycotripeptoid core mimicking a cluster of Tn at the surface of tumor cells (B epitope), conjugated to the OVA 323-339 peptide (T-cell epitope) and a Toll-like receptor 7 (TLR7) agonist for potent adjuvanticity. "
2.	Lymphoma (Lymphomas) 10/01/2002 - "Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA(323-339)/I-Ad. " 01/01/1999 - "However, we have found that treatment of A20-HL murine B lymphoma cells with CT severely inhibits the presentation of ovalbumin (OVA) to cells of the T cell clone 42-6A specific for OVA(323-339)/I-Ad, whereas it does not affect the presentation of OVA(323-339) peptide. " 04/01/1999 - "Irradiation of A20.2J mouse B-lymphoma cells enhanced their antigen-presenting ability to induce interleukin-2 (IL-2) production by 42-6A T cells specific for ovalbumin (OVA)323-339/I-Ad. "
3.	Pneumonia (Pneumonitis) 05/01/2010 - "Evaluated by hematoxylin/eosin and major basic protein immunohistochemical stainings, OVA and OVA 323-339 induced similar lung inflammation. "
4.	Hypothermia 10/01/2002 - "OVA(323-339):I-A complexes were formed from OVA within 10 min with B6D2F1 macrophages but not until 20 min with C57BL/6 or DBA/2 macrophages, and OVA processing was more resistant to inhibition of late endocytic function by hypothermia (18 degrees C) in B6D2F1 than C57BL/6 or DBA/2 macrophages. "
5.	Food Hypersensitivity (Food Allergy) 10/01/1994 - "An analog peptide of the OVA 323-339 which is known to strongly bind to I-Ad partially inhibited the response of the TCL to OVA 323-339 presented by HLA-DR10, raising the possibility of peptide-based immunotherapy of food allergy."

Related Drugs and Biologics

1.	Epitopes
2.	Peptides (Polypeptides)
3.	Ovalbumin
4.	Antigens
5.	Toll-Like Receptor 7
6.	Peptide T
7.	Vaccines
8.	Proteins (Proteins, Gene)
9.	Interleukin-2 (IL2)
10.	Immunoglobulin M (IgM)

Related Therapies and Procedures

1.	Immunotherapy